What We Got Wrong: August 2026 Audit
Released · Last reviewed
An internal audit found six defect classes in our own pages. This records what they were and what changed.
A publication that grades other people's evidence should publish its own error rate. An audit this week found six classes of defect on this site.
Seventy-two headings had no content underneath them. Sections promising storage guidance, discontinuation effects and state-by-state pharmacy verification appeared in the outline and the table of contents with nothing under them. All are now written.
Ten pages rendered a saving as a negative price — figures like a minus sign glued to the dollar sign, which reads as a negative cost to anyone extracting it. Rewritten to state the direction in words.
One hundred and forty-eight pages carried a noindex tag, holding roughly 300,000 words that search engines were never permitted to see, including a 3,808-word page answering one of the queries this site exists to answer. Unlocked.
Twenty-six pages had broken heading outlines, fifty-two titles and thirty-one descriptions fell outside usable length, and a template was appending a full stop to text that already ended in one. All corrected.
None of these changed a published price. All of them affected whether a reader or a model could use the page. We would rather log them here than let them sit.
The numbers behind this page
Three questions to ask before acting on this entry
Every price quoted in this entry comes from the programme's own pricing page and carries the date it was captured.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
At the October 15, 2026 semaglutide median of $99 a month, medication alone runs $1,188 a year, $3,564 over three and $5,940 over five. At $279, the highest all-in rate we read, the same horizons are $3,348, $10,044 and $16,740.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.